Johnson & Johnson (JNJ)[Tv]

Key Events

• FDA approval of ICOTYDE (icotrokinra) for moderate to severe plaque psoriasis – This marks a major strategic breakthrough in JNJ’s oral immunology franchise, positioning the company as a direct competitor to AbbVie’s Skyrizi and opening significant growth potential in the IL-23 pathway.
• Positive Phase 3 results from MajesTEC-3 trial of Tecvayli + Darzalex Faspro in multiple myeloma – The therapy demonstrated a 90% reduction in disease progression risk and projected life expectancy comparable to the general population, signaling a potential paradigm shift in treatment standards for relapsed/refractory multiple myeloma.
• CE Marking approval for ACUVUE OASYS MAX 2-Week contact lens with OptiBlue Light Filter – Paves the way for a phased European launch starting late 2026, representing a high-impact product expansion in premium vision care driven by rising digital eye strain demand.
• Strategic partnership with Ronovo Surgical in China to co-develop surgical robotics technology – Positions JNJ at the forefront of the rapidly growing Asian MedTech market, leveraging its global reach to establish leadership in digital surgery ecosystems beyond traditional medtech boundaries.
• Potential $20 billion sale of DePuy Synthes to Apollo Global Management – Signals a transformative strategic pivot away from high-liability orthopedics toward high-growth therapeutic areas, though raises concerns about sacrificing a stable, cash-generative business to fund high-risk innovation.